Cargando…
Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)
Grade 3 (G3, poorly differentiated) is an important treatment-decision factor in stage II colon cancer, but no unified diagnostic criteria are established. According to previous studies, an intratumoural poorly differentiated area with no glandular formation (POR) that fills the microscopic field of...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690643/ https://www.ncbi.nlm.nih.gov/pubmed/32868525 http://dx.doi.org/10.1097/PAS.0000000000001570 |
_version_ | 1783614114842542080 |
---|---|
author | Ueno, Hideki Ishiguro, Megumi Nakatani, Eiji Ishikawa, Toshiaki Uetake, Hiroyuki Matsui, Shigeyuki Teramukai, Satoshi Murotani, Kenta Ajioka, Yoichi Shimazaki, Hideyuki Maeda, Atsuyuki Takuma, Kunio Yoshida, Takefumi Kambara, Takeshi Matsuda, Keiji Takagane, Akinori Tomita, Naohiro Sugihara, Kenichi |
author_facet | Ueno, Hideki Ishiguro, Megumi Nakatani, Eiji Ishikawa, Toshiaki Uetake, Hiroyuki Matsui, Shigeyuki Teramukai, Satoshi Murotani, Kenta Ajioka, Yoichi Shimazaki, Hideyuki Maeda, Atsuyuki Takuma, Kunio Yoshida, Takefumi Kambara, Takeshi Matsuda, Keiji Takagane, Akinori Tomita, Naohiro Sugihara, Kenichi |
author_sort | Ueno, Hideki |
collection | PubMed |
description | Grade 3 (G3, poorly differentiated) is an important treatment-decision factor in stage II colon cancer, but no unified diagnostic criteria are established. According to previous studies, an intratumoural poorly differentiated area with no glandular formation (POR) that fills the microscopic field of a ×40 objective lens was an essential factor that defined G3. We aimed to prospectively validate this in a randomized controlled study of adjuvant chemotherapy (SACURA trial). We enrolled 991 patients with stage II colon cancer. POR was graded according to the ×40 objective lens rule and the intensity of poorly differentiated clusters (Grade(POR)), and its prognostic power was compared with that of the conventional tumor grade on the basis of predominant histology rule (Grade(conv)). According to Grade(POR), 313, 526, and 152 tumors were classified as G1(POR), G2(POR), and G3(POR), respectively, and the 5-year relapse-free survival (RFS) rates were 91.1%, 82.9%, and 74.7%, respectively (P<0.0001). When G3(POR) and G3(conv) were alternatively added to the prognostic model consisting of 8 conventional factors, only G3(POR) was a significant factor for RFS (P=0.040, Wald test). The adverse impact of G3(POR) on RFS was greater in the microsatellite stable/microsatellite instability–low subset than that in the full analysis set. In the microsatellite stable/microsatellite instability–low subset, the 5-year RFS rate of patients with G3(POR) tumors in the chemotherapy group achieved greater improvement (9.1%) than the surgery-alone group. The least differentiation policy with the ×40 objective lens rule may be highlighted as the diagnostic criterion for G3 because of its validated prognostic value. |
format | Online Article Text |
id | pubmed-7690643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-76906432020-12-01 Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) Ueno, Hideki Ishiguro, Megumi Nakatani, Eiji Ishikawa, Toshiaki Uetake, Hiroyuki Matsui, Shigeyuki Teramukai, Satoshi Murotani, Kenta Ajioka, Yoichi Shimazaki, Hideyuki Maeda, Atsuyuki Takuma, Kunio Yoshida, Takefumi Kambara, Takeshi Matsuda, Keiji Takagane, Akinori Tomita, Naohiro Sugihara, Kenichi Am J Surg Pathol Original Articles Grade 3 (G3, poorly differentiated) is an important treatment-decision factor in stage II colon cancer, but no unified diagnostic criteria are established. According to previous studies, an intratumoural poorly differentiated area with no glandular formation (POR) that fills the microscopic field of a ×40 objective lens was an essential factor that defined G3. We aimed to prospectively validate this in a randomized controlled study of adjuvant chemotherapy (SACURA trial). We enrolled 991 patients with stage II colon cancer. POR was graded according to the ×40 objective lens rule and the intensity of poorly differentiated clusters (Grade(POR)), and its prognostic power was compared with that of the conventional tumor grade on the basis of predominant histology rule (Grade(conv)). According to Grade(POR), 313, 526, and 152 tumors were classified as G1(POR), G2(POR), and G3(POR), respectively, and the 5-year relapse-free survival (RFS) rates were 91.1%, 82.9%, and 74.7%, respectively (P<0.0001). When G3(POR) and G3(conv) were alternatively added to the prognostic model consisting of 8 conventional factors, only G3(POR) was a significant factor for RFS (P=0.040, Wald test). The adverse impact of G3(POR) on RFS was greater in the microsatellite stable/microsatellite instability–low subset than that in the full analysis set. In the microsatellite stable/microsatellite instability–low subset, the 5-year RFS rate of patients with G3(POR) tumors in the chemotherapy group achieved greater improvement (9.1%) than the surgery-alone group. The least differentiation policy with the ×40 objective lens rule may be highlighted as the diagnostic criterion for G3 because of its validated prognostic value. Lippincott Williams & Wilkins 2020-12 2020-08-28 /pmc/articles/PMC7690643/ /pubmed/32868525 http://dx.doi.org/10.1097/PAS.0000000000001570 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Articles Ueno, Hideki Ishiguro, Megumi Nakatani, Eiji Ishikawa, Toshiaki Uetake, Hiroyuki Matsui, Shigeyuki Teramukai, Satoshi Murotani, Kenta Ajioka, Yoichi Shimazaki, Hideyuki Maeda, Atsuyuki Takuma, Kunio Yoshida, Takefumi Kambara, Takeshi Matsuda, Keiji Takagane, Akinori Tomita, Naohiro Sugihara, Kenichi Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) |
title | Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) |
title_full | Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) |
title_fullStr | Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) |
title_full_unstemmed | Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) |
title_short | Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) |
title_sort | optimal criteria for g3 (poorly differentiated) stage ii colon cancer: prospective validation in a randomized controlled study (sacura trial) |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690643/ https://www.ncbi.nlm.nih.gov/pubmed/32868525 http://dx.doi.org/10.1097/PAS.0000000000001570 |
work_keys_str_mv | AT uenohideki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT ishiguromegumi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT nakatanieiji optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT ishikawatoshiaki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT uetakehiroyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT matsuishigeyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT teramukaisatoshi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT murotanikenta optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT ajiokayoichi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT shimazakihideyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT maedaatsuyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT takumakunio optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT yoshidatakefumi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT kambaratakeshi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT matsudakeiji optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT takaganeakinori optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT tomitanaohiro optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial AT sugiharakenichi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial |